FDA proposes overhaul of fast-track process for cancer meds
Illustration: Rebecca Zisser/Axios The Food and Drug Administration is eyeing policy changes that could make drugmakers conduct more stringent trials to win fast-track approvals of cancer drugs. Why it matters: The agency's accelerated approval process has drawn fire for the way it allows manufacturers to launch products based on preliminary evidence and charge high prices before they complete trials. Some […]
Continue reading »